SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
Former Rep. Eric Cantor speaks during a portrait unveiling ceremony in the U.S. Capitol on September 15, 2026 in Washington, DC.
(Photo by Heather Diehl/Getty Images)
'A Match Made in Hell': Former GOP House Leader to Head Big Pharma Lobby
"Cantor, like PhRMA, is an experienced reverse Robin Hood, legislating money away from working families and toward giant corporations."
Sep 29, 2026
In what advocates for lower drug prices call "a match made in hell," one of the pharmaceutical industry's most powerful lobbying groups is tapping a former Republican leader in the US House of Representatives to head its political operations.
Pharmaceutical Research and Manufacturers of America (PhRMA) named former Rep. Eric Cantor (R-Va.) as its president and CEO on Tuesday amid what is shaping up to be a major fight over the government's ability to regulate prescription drug prices.
Cantor served in Congress from 2001-14 and was named House majority leader in 2011. He resigned in 2014 after losing his Republican primary in a stunning upset to the Tea Party-backed former Rep. Dave Brat.
According to recent polling from KFF, more than half of US adults say they worry about affording prescription drugs and nearly three-quarters say the government should do more to limit prices.
PhRMA emphasized that Cantor's appointment to replace the outgoing CEO Stephen Ubl comes at "a pivotal moment for America’s biopharmaceutical industry."
It is certainly spending like it. As Politico reported on Tuesday, pressure from voters to address the affordability of prescription drugs has been met with an unprecedented lobbying blitz by PhRMA, which poured a record $38 million into efforts to keep Capitol Hill in line.
PhRMA said Cantor’s “global business acumen coupled with policy and political experience at the highest levels of government make him an ideal person to lead PhRMA during this critical next chapter.”
Peter Maybarduk, the access to medicines director for the consumer watchdog group Public Citizen, agreed that Cantor was a perfect fit for PhRMA, but for very different reasons.
"Cantor, like PhRMA, is an experienced reverse Robin Hood, legislating money away from working families and toward giant corporations," Maybarduk said.
During his tenure in Congress, Cantor received roughly $900,000 from the pharmaceutical and health product industry, putting him 19th among all House candidates between 1999 and 2018, according to a JAMA Internal Medicine study of data from the Center for Responsive Politics.
That spending paid dividends, with Cantor voting against legislation aimed at lowering prescription drugs—including one bill in 2003 that would have allowed Americans to import low-cost prescription drugs from abroad and another in 2007 that would have required the federal government to negotiate drug prices for Medicare recipients.
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
In what advocates for lower drug prices call "a match made in hell," one of the pharmaceutical industry's most powerful lobbying groups is tapping a former Republican leader in the US House of Representatives to head its political operations.
Pharmaceutical Research and Manufacturers of America (PhRMA) named former Rep. Eric Cantor (R-Va.) as its president and CEO on Tuesday amid what is shaping up to be a major fight over the government's ability to regulate prescription drug prices.
Cantor served in Congress from 2001-14 and was named House majority leader in 2011. He resigned in 2014 after losing his Republican primary in a stunning upset to the Tea Party-backed former Rep. Dave Brat.
According to recent polling from KFF, more than half of US adults say they worry about affording prescription drugs and nearly three-quarters say the government should do more to limit prices.
PhRMA emphasized that Cantor's appointment to replace the outgoing CEO Stephen Ubl comes at "a pivotal moment for America’s biopharmaceutical industry."
It is certainly spending like it. As Politico reported on Tuesday, pressure from voters to address the affordability of prescription drugs has been met with an unprecedented lobbying blitz by PhRMA, which poured a record $38 million into efforts to keep Capitol Hill in line.
PhRMA said Cantor’s “global business acumen coupled with policy and political experience at the highest levels of government make him an ideal person to lead PhRMA during this critical next chapter.”
Peter Maybarduk, the access to medicines director for the consumer watchdog group Public Citizen, agreed that Cantor was a perfect fit for PhRMA, but for very different reasons.
"Cantor, like PhRMA, is an experienced reverse Robin Hood, legislating money away from working families and toward giant corporations," Maybarduk said.
During his tenure in Congress, Cantor received roughly $900,000 from the pharmaceutical and health product industry, putting him 19th among all House candidates between 1999 and 2018, according to a JAMA Internal Medicine study of data from the Center for Responsive Politics.
That spending paid dividends, with Cantor voting against legislation aimed at lowering prescription drugs—including one bill in 2003 that would have allowed Americans to import low-cost prescription drugs from abroad and another in 2007 that would have required the federal government to negotiate drug prices for Medicare recipients.
In what advocates for lower drug prices call "a match made in hell," one of the pharmaceutical industry's most powerful lobbying groups is tapping a former Republican leader in the US House of Representatives to head its political operations.
Pharmaceutical Research and Manufacturers of America (PhRMA) named former Rep. Eric Cantor (R-Va.) as its president and CEO on Tuesday amid what is shaping up to be a major fight over the government's ability to regulate prescription drug prices.
Cantor served in Congress from 2001-14 and was named House majority leader in 2011. He resigned in 2014 after losing his Republican primary in a stunning upset to the Tea Party-backed former Rep. Dave Brat.
According to recent polling from KFF, more than half of US adults say they worry about affording prescription drugs and nearly three-quarters say the government should do more to limit prices.
PhRMA emphasized that Cantor's appointment to replace the outgoing CEO Stephen Ubl comes at "a pivotal moment for America’s biopharmaceutical industry."
It is certainly spending like it. As Politico reported on Tuesday, pressure from voters to address the affordability of prescription drugs has been met with an unprecedented lobbying blitz by PhRMA, which poured a record $38 million into efforts to keep Capitol Hill in line.
PhRMA said Cantor’s “global business acumen coupled with policy and political experience at the highest levels of government make him an ideal person to lead PhRMA during this critical next chapter.”
Peter Maybarduk, the access to medicines director for the consumer watchdog group Public Citizen, agreed that Cantor was a perfect fit for PhRMA, but for very different reasons.
"Cantor, like PhRMA, is an experienced reverse Robin Hood, legislating money away from working families and toward giant corporations," Maybarduk said.
During his tenure in Congress, Cantor received roughly $900,000 from the pharmaceutical and health product industry, putting him 19th among all House candidates between 1999 and 2018, according to a JAMA Internal Medicine study of data from the Center for Responsive Politics.
That spending paid dividends, with Cantor voting against legislation aimed at lowering prescription drugs—including one bill in 2003 that would have allowed Americans to import low-cost prescription drugs from abroad and another in 2007 that would have required the federal government to negotiate drug prices for Medicare recipients.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.
To inform. To inspire. To ignite change for the common good.
News & Opinion
Trending
Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit
Privacy Policy